Register for free to
view the full innovation profile.
“Hyperbranched poly(ß-amino ester)-based injectable hydrogel encapsulating ADSCS promotes diabetic wound healing”
About
UCD hosts the Charles Institute the first academic institute devoted to dermatology in Ireland. Researchers there have developed a range of novel biomaterials based on hydrogels that act as biodegradable skin substitute. This has been developed for difficult to heal wounds, specifically for diabetic wound healing, (the diabetic foot ulcers (DFUs) market is expected to reach $9 billion in annual cost). The modified hydrogels with optimized degradation profiles encapsulating ADSCs are used as injectable hydrogels to treat two different types of humanized excisional wounds – acute wounds with faster healing rates and diabetic wounds with slower healing and neo-tissue formation. Patent protected Technology Patent Application No. 1704671.5
Key Benefits
Novel optimization of biomaterials for tissue regeneration has been achieved through the tuning of degradation rates to match the wound healing process.
Applications
Diabetic wound care Reduced scaring technology